CNS Pharmaceuticals, Inc.
CNSP
$1.12
-$0.005-0.44%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.98% | -1.96% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -43.15% | 122.65% | |||
| Operating Income | 43.15% | -122.65% | |||
| Income Before Tax | 43.34% | -121.51% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 43.34% | -121.51% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 43.34% | -121.51% | |||
| EBIT | 43.15% | -122.65% | |||
| EBITDA | 43.16% | -122.69% | |||
| EPS Basic | 76.60% | -- | |||
| Normalized Basic EPS | 76.60% | -- | |||
| EPS Diluted | 76.55% | -- | |||
| Normalized Diluted EPS | 76.60% | -- | |||
| Average Basic Shares Outstanding | 142.13% | -- | |||
| Average Diluted Shares Outstanding | 142.13% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||